Mundipharma confirms its commitment to more than 66 million people in the world suffering from Glaucoma. By purchasing Merck Sharp Dohme (MSD) ophthalmology products in more than 54 countries, the company manages to position itself in leadership positions with medicines of recognized trajectory and quality for the treatment of this pathology.

Pioneers in the health and care of the human being. Innovative medicine made accessible to those who need it